Mostrar el registro sencillo del ítem
dc.contributor.author | Genescà, E | |
dc.contributor.author | Lazarenkov, A | |
dc.contributor.author | Morgades, M | |
dc.contributor.author | Berbis, G | |
dc.contributor.author | Ruiz-Xivillé, Neus | |
dc.contributor.author | Gómez-Marzo, P | |
dc.contributor.author | Ribera, J | |
dc.contributor.author | Juncà, J | |
dc.contributor.author | González-Pérez, A | |
dc.contributor.author | Mercadal, S | |
dc.contributor.author | Guardia, R | |
dc.contributor.author | Artola, M T | |
dc.contributor.author | Moreno, M J | |
dc.contributor.author | Martinez Lopez, Joaquin | |
dc.contributor.author | Zamora, L | |
dc.contributor.author | Barba, P | |
dc.contributor.author | Gil, C | |
dc.contributor.author | Tormo, M | |
dc.contributor.author | Cladera, A | |
dc.contributor.author | Novo, A | |
dc.contributor.author | Pratcorona, M | |
dc.contributor.author | Nomdedeu, J | |
dc.contributor.author | González-Campos, J | |
dc.contributor.author | Almeida, M | |
dc.contributor.author | Cervera, J | |
dc.contributor.author | Montesinos, P | |
dc.contributor.author | Batlle, M | |
dc.contributor.author | Vives, S | |
dc.contributor.author | Esteve, J | |
dc.contributor.author | Feliu, E | |
dc.contributor.author | Solé, F | |
dc.contributor.author | Orfao, A | |
dc.contributor.author | Ribera, J M | |
dc.date.accessioned | 2018-11-14T12:31:59Z | |
dc.date.available | 2018-11-14T12:31:59Z | |
dc.date.issued | 2018-07-24 | |
dc.identifier.citation | J Hematol Oncol. 2018; 11 (11) : 96. | es_ES |
dc.identifier.issn | 1756-8722 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/6591 | |
dc.description.abstract | Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation. | es_ES |
dc.description.sponsorship | We would like to thank Ernest Terribes for his advice and help in qPCR design andanalysisaswellasAlbaGarcíaandJes ús-María Hernández-Rivas for providing some DNA samples. We are grateful to Isabel Granada for her helpful advice regarding cytogenetic and FISH analyses. This project was supported by the Asociación Española C ontra el Cáncer, AECC (project ref.: GC16173697BIGA), by CERCA Program/Generalitat de Catalunya, the Catalan Government: 2014-SGR225 (GRE), Obra Social “ La Caixa ” and by Celgene Spain. E. Genescà is the recipient of agrant from the Spanish Health Ministry (ISCIII, CA12/00468) and an unrestricted grant from Gilead.A. Gonzalez-Perez is supported by a Ramon y Cajal fellowship (RYC-2013-14554) of the Educational Ministry (Madrid, Spain). This work was also partially supported by FEDER funds from the ISCIII (PT13/0010/0026, CIBERONC (CB16/12/00284 and CB16/12/00400), Madrid, Spain). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BioMed Central (BMC) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | CDKN2A/ARF | es_ES |
dc.subject | CDKN2B | es_ES |
dc.subject | MRD | es_ES |
dc.subject | Prognosis | es_ES |
dc.subject | T-ALL | es_ES |
dc.title | Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 30041662 | es_ES |
dc.format.volume | 11 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 96 | es_ES |
dc.identifier.doi | 10.1186/s13045-018-0639-8 | es_ES |
dc.contributor.funder | Asociación Española Contra el Cáncer | |
dc.contributor.funder | Government of Catalonia (España) | |
dc.contributor.funder | Fundación La Caixa | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.description.peerreviewed | Sí | |
dc.identifier.e-issn | 1756-8722 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1186/s13045-018-0639-8. | es_ES |
dc.identifier.journal | Journal of hematology & oncology | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Unidades técnicas::Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/GC16173697BIGA | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/2014-SGR225 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/CA12/00468 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RYC-2013-14554 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PT13/0010/0026 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/CB16/12/00284 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/CB16/12/00400 | es_ES |
dc.rights.accessRights | open access | es_ES |